Preliminary Consequences of Blood Pressure Management and Blood Homocysteine Levels with Perindopril in Newly Diagnosed Hypertensive Patients in the Vietnamese Population.

IF 1.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Hypertension Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI:10.1155/2023/1933783

Son Kim Tran, An Bao Truong, Phi Hoang Nguyen, Toan Hoang Ngo, Tuyen Long Vu, Khoa Dang Dang Tran, Phuong Minh Vo, Bao The Nguyen, Tuong Le Trong Huynh, Kien Trung Nguyen, Hung Do Tran

{"title":"Preliminary Consequences of Blood Pressure Management and Blood Homocysteine Levels with Perindopril in Newly Diagnosed Hypertensive Patients in the Vietnamese Population.","authors":"Son Kim Tran, An Bao Truong, Phi Hoang Nguyen, Toan Hoang Ngo, Tuyen Long Vu, Khoa Dang Dang Tran, Phuong Minh Vo, Bao The Nguyen, Tuong Le Trong Huynh, Kien Trung Nguyen, Hung Do Tran","doi":"10.1155/2023/1933783","DOIUrl":null,"url":null,"abstract":"Background: Perindopril is an ACE inhibitor that aids in both blood pressure regulation and homocysteine reduction.Objectives: Our study aimed to evaluate the results of controlling blood pressure and blood homocysteine levels by perindopril in patients with primary hypertension.Materials and methods: A cross-sectional descriptive study with a longitudinal follow-up was conducted on 105 primary hypertensive patients treated with perindopril.Results: The results of our study showed that after 6 weeks of treatment with perindopril, the proportion of patients with the target blood pressure (BP) level accounted for 70.5%, the rate of grade 1 hypertension decreased from 61.0% to 25.7%, grade 2 blood pressure decreased from 17.1% to 3.8%, and there was no case of grade 3 hypertension. At the same time, we also found that the rate of BP control in the group of patients who controlled Hcy below a threshold of 15 μmol/L was significantly higher than in the other group (p < 0.05). Concerning the efficacy of decreasing homocysteine in blood, we discovered that after 6 weeks of treatment with perindopril, the proportion of patients with elevated homocysteine reduced considerably from 74.3% to 40% (p < 0.05). In addition, the homocysteine concentration was 4.33 mol/L lower after treatment than before treatment (95% CI: 3.69-4.97) (p < 0.05).Conclusion: Perindopril helps control blood pressure and reduces blood homocysteine levels in patients with primary hypertension.","PeriodicalId":14132,"journal":{"name":"International Journal of Hypertension","volume":"2023 ","pages":"1933783"},"PeriodicalIF":1.9000,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599879/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/1933783","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Perindopril is an ACE inhibitor that aids in both blood pressure regulation and homocysteine reduction.

Objectives: Our study aimed to evaluate the results of controlling blood pressure and blood homocysteine levels by perindopril in patients with primary hypertension.

Materials and methods: A cross-sectional descriptive study with a longitudinal follow-up was conducted on 105 primary hypertensive patients treated with perindopril.

Results: The results of our study showed that after 6 weeks of treatment with perindopril, the proportion of patients with the target blood pressure (BP) level accounted for 70.5%, the rate of grade 1 hypertension decreased from 61.0% to 25.7%, grade 2 blood pressure decreased from 17.1% to 3.8%, and there was no case of grade 3 hypertension. At the same time, we also found that the rate of BP control in the group of patients who controlled Hcy below a threshold of 15 μmol/L was significantly higher than in the other group (p < 0.05). Concerning the efficacy of decreasing homocysteine in blood, we discovered that after 6 weeks of treatment with perindopril, the proportion of patients with elevated homocysteine reduced considerably from 74.3% to 40% (p < 0.05). In addition, the homocysteine concentration was 4.33 mol/L lower after treatment than before treatment (95% CI: 3.69-4.97) (p < 0.05).

Conclusion: Perindopril helps control blood pressure and reduces blood homocysteine levels in patients with primary hypertension.

Abstract Image

查看原文本刊更多论文

在越南人群中，新诊断的高血压患者使用培哚普利进行血压管理和血液同型半胱氨酸水平的初步后果。

背景：培哚普利是一种ACE抑制剂，有助于调节血压和降低同型半胱氨酸。目的：本研究旨在评价培哚普利控制原发性高血压患者血压和血液同型半胱氨酸水平的效果。材料和方法：对105例接受培哚普利治疗的原发性高血压患者进行横断面描述性研究和纵向随访。结果：我们的研究结果表明培哚普利治疗周，达到目标血压（BP）水平的患者比例占70.5%，1级高血压发生率从61.0%下降到25.7%，2级高血压从17.1%下降到3.8%，无3级高血压病例。同时，我们还发现，在将Hcy控制在阈值15以下的患者组中，BP控制率 μmol/L显著高于对照组（p < 0.05）。关于降低血液中同型半胱氨酸的疗效，我们发现在6 培哚普利治疗数周后，同型半胱氨酸升高的患者比例从74.3%显著降低到40%（p < 0.05）。此外，同型半胱氨酸浓度为4.33 mol／L治疗后低于治疗前（95%可信区间：3.69～4.97）（p < 结论：培哚普利有助于控制原发性高血压患者的血压，降低血液同型半胱氨酸水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hypertension Medicine-Internal Medicine

CiteScore

4.00

自引率

5.30%

发文量

期刊介绍： International Journal of Hypertension is a peer-reviewed, Open Access journal that provides a forum for clinicians and basic scientists interested in blood pressure regulation and pathophysiology, as well as treatment and prevention of hypertension. The journal publishes original research articles, review articles, and clinical studies on the etiology and risk factors of hypertension, with a special focus on vascular biology, epidemiology, pediatric hypertension, and hypertensive nephropathy.